IMMUKNOW® BIBLIOGRAPHY OF PUBLICATIONS – SOLID ORGAN TRANSPLANTATION ADDENDUM SOLID ORGAN TRANSPLANT ABSTRACTS, PRESENTATIONS OR POSTERS
2012
Adabala M, Jain A, Kapur G, Baracco R, Kirby J, Bartow C, Mattoo T. ImmuKnow (Cylex) in pediatric renal transplant patients. Paper presented at: American Transplant Congress June 2012; Boston, MA.
Bini F, Miserere S, Morosini M, Grasso A, Cova E, Pellegrini C, D'Armini AM, Meloni F. Experience with Cylex immune cell function assay in clinical immune monitoring of lung transplant recipients. Paper presented at: International Society for Heart and Lung Transplantation Annual Meeting April 2012; Prague, Czech Republic.
Burdette S, Carmen T, Klein J. Low Immune cell function values as a risk factor for current or subsequent infection. Paper presented at: American Transplant Congress June 2012; Boston, MA.
Chang GY, Vo A, Kahwaji J, Toyoda M, Choi J, Peng A, Villicana R, Jordan S. Viral infections and CD4+ T-cell function (ImmuKnow®) in highly-sensitized kidney transplant recipients treated with alemtuzumab induction. Paper presented at: American Transplant Congress June 2012; Boston, MA.
Guo Z, Ju W, Ling X, Tai Q, Wu L, Wang D, He X. Can immune cell function assay identify patients at risk of infection or rejection? A meta-analysis. Paper presented at: American Transplant Congress June 2012; Boston, MA.
Heikal N, Hil H, Martins T, Pavlov I, Wilson A, Stehlik J, Kfoury A, Delgado J, Bader F.TNF-α and IL-8 predict cardiac vasculopathy after cardiac transplantation. Paper presented at: International Society for Heart and Lung Transplantation Annual Meeting April 2012; Prague, Czech Republic.
Khasawneh EA, Gupta S, Shahlaee A, Theriaque D, Garrett T, Shuster J, Dharnidharka V. Immune biomarker panel measuring both extremes of immunosuppression associate with acute rejection (AR) or major infection events (MIE). Paper presented at: American Transplant Congress June 2012; Boston, MA.
Khattak MW, Abi Rached J, Aggarwal S, Ahmed I, Malat G, Ranganna K, Guy S, Doyle A. Adenosine triphosphate (ATP) levels at the time of kidney transplant evaluation. Paper presented at: National Kidney Foundation Annual Meeting May 2012; Washington, D.C.
Khuu T, Baas AS, Cheng R, Cruz D, Hickey A, Kubak B, Nsair A, Holt C, Deng MC.Pomegranate-induced alterations in tacrolimus concentration. Paper presented at: International Society for Heart and Lung Transplantation Annual Meeting April 2012; Prague, Czech Republic.
Knight R, Patel S, DeVos J, Gaber AO. The utility of the Cylex immune monitoring assay for detection of posttransplant pancreas opportunistic infections and rejections. Paper presented at: American Transplant Congress June 2012; Boston, MA.
Krecko KR, Yang HC, Waybil MM. The importance of monitoring mycophenolic acid area-under-curve (MPA AUC) levels to prevent the development of HLA antibodies in renal transplant patients. Paper presented at: American Transplant Congress June 2012; Boston, MA.
Lau YW, Yeo WS, Ng KH, Seah CC, Chan YH, Yap HK. Role of immune cell function assay in predicting risk
of BK viremia in pediatric renal transplant recipients. Paper presented at: American Transplant Congress June 2012; Boston, MA.
Minces L, Clancy CJ, Shields RK, Kwak EJ, Silveira F, Toyoda Y, Bermudez C, Pilewski J, Crespo M, Nguyen MH. Ganciclovir-resistant (GCV-R) CMV is common among lung transplant recipients (LTR) receiving alemtuzumab induction and valganciclovir prophylaxis (VGC PX), and treatment with foscarnet (FOS) is both ineffective and toxic. Paper presented at: International Society for Heart and Lung Transplantation Annual Meeting April 2012; Prague, Czech Republic.
Minh-Tri Nguyen, Shuqing Liu, Syamala Kalyanasundaram, Steven Paraskevas, Jean Tchervenkov. Enhanced immune function and pro-inflammatory cytokines in highly-sensitized patients awaiting kidney transplantation. Paper presented at: American Transplant Congress June 2012; Boston, MA.
Mizuno S, Nakatani K, Muraki Y, Kuriyama N, Osawa I, Kishiwada M, Hamada T, Usui M, Sakurai H, Tabata M, Isaji S. Prediction of morbidity and mortality in living donor liver transplant patients using combination assays of immune function and CYP3A5 genotype. Paper presented at: American Transplant Congress June 2012; Boston, MA.
Oh EJ, Jo Y, Kim Y, Park YJ, Han K. CD4 T-cell function assay by Cylex ImmuKnow and lymphocyte subset recovery following allogenic stem cell transplantation. Paper presented at: American Transplant Congress June 2012; Boston, MA.
Rafiei M, Patel J, Kittleson M, Patel N, Stern L, Azarbal B, Czer L, Trento A, Kobashigawa J. First-year rejection and Cylex scores suggest the importance of acute events in the development of cardiac allograft vasculopath. Paper presented at: International Society for Heart and Lung Transplantation Annual Meeting April 2012; Prague, Czech Republic.
Takita M, Matsumoto S, Shimoda M, Itoh T, Iwahashi S, Chujo D, Kanak M, Onaca N, Naziruddin B, Levy MF. Impact of T-cell depletion protocol on lymphocyte and immune function assay profiles in clinical islet cell transplantation. Paper presented at: American Transplant Congress June 2012; Boston, MA.
Tan HP, Shapiro R, Donaldson J, Basu A, McCauley J, Wu C, Shah N, Randhawa P, Sturdevant M, Wijkstrom M, Humar A. Alemtuzumab pretreatment and weaning of tacrolimus monotherapy: experience of first 200 living donor kidney transplants with mean 77 months follow-up. Paper presented at: American Transplant Congress June 2012; Boston, MA.
Tan HP, Shapiro R, Donaldson J, Basu A, Sturdevant M, Lopez R, Wijkstrom M, Humar A. 670 living donor kidney transplants using alemtuzumab pretreatment and tacrolimus monotherapy: 9-year experience. Paper presented at: American Transplant Congress June 2012; Boston, MA.
Tan HP, Shapiro R, Donaldson J, Basu A, Sturdevant M, Lopez R, Wijkstrom M, Humar A. A comparative study of weaning vs. non-weaning of tacrolimus monotherapy after alemtuzumab pretreatment in 300 living donor kidney transplant recipients. Paper presented at: American Transplant Congress June 2012; Boston, MA.
Wojciechowski D, Lee B, Baxter-Lowe L. Immune function assessments of renal transplant recipients induced with rATG or basiliximab. Paper presented at: American Transplant Congress June 2012; Boston, MA.
The UK government is building a national database of medical records, aproject which many doctors oppose; in a Medix poll in November, over half ofall GPs said they would not upload their patients’ data without consent [1] [2]. The following week, a Joseph Rowntree Reform Trust poll revealed that 53% ofpatients oppose a central medical records database with no right to opt out. A campaign, The
BHADRA PHARMA CARE O u r ph a r m a c e u t i c a l m a n u f a c t u r i n g pla n t is eq u i p p e d wit h m o d e r n hig h- sp e e d m a c h i n e s an d inte g r a t e d pa c k a g i n g line s to be co s t effi ci e n t. Ext e n s i v e us e of vis u a l ins p e c t i o n m a c h i n e s , m u l ti- stati o n ta bl e t pr e s s e s , attr a c t i v e pri m a r y pa c k i n g , liq ui d